Stephen I. Deutsch

Dr. Stephen I. Deutsch

1. Department of Psychiatry and Behavioral Sciences, Eastern Virginia Medical School, 825 Fairfax Avenue, Suite 710, Norfolk, VA 23507, USA
+1

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2010 in Clinical Neuropharmacology
Verified
Journal Article
Closed access
SDStephen I. Deutsch
Stephen I. Deutsch
MUMaria R. Urbano
Maria R. Urbano
SNSerina A. Neumann
Serina A. Neumann
JBJessica A. Burket
Jessica A. Burket
EKElionora Katz
Elionora Katz
The core dysfunctions of autism spectrum disorders, which include autistic disorder, Asperger disorder, and pervasive developmental disorder not otherwise specified, include deficits in socialization and communication and a need for the preservation of "sameness;" intellectual impairment and epilepsy are common comorbidities. Data suggest that pathological involvement of cholinergic nuclei and altered expression of acetylcholine receptors, particularly nicotinic acetylcholine receptors, occur in brain of persons with autistic disorder. However, many of these studies involved postmortem tissue from small samples of primarily adult persons. Thus, the findings may reflect compensatory changes and may relate more closely to intellectual impairment and the confounding effects of seizures and medications, as opposed to the core dysfunctions of autism. Nonetheless, because of the roles played by acetylcholine receptors in general, and nicotinic acetylcholine receptors in particular, in normal processes of attention, cognition, and memory, selective cholinergic interventions should be explored for possible therapeutic effects. Additionally, there are electrophysiological data that complement the clinical observations of frequent comorbid seizure disorders in these patients, suggesting a disturbance in the balance of excitatory and inhibitory tone in the brains of persons with autistic disorders. Conceivably, because the alpha7 nicotinic acetylcholine receptor is located on the surface of gamma-aminobutyric acid inhibitory neurons, selective stimulation of this receptor would promote gamma-aminobutyric acid's release and restore diminished inhibitory tone. The development of agonists and partial agonists for nicotinic acetylcholine receptors and positive allosteric modulators that enhance the efficiency of coupling between the binding of agonist and channel opening should facilitate consideration of clinical trials.

1 August 2013 in Schizophrenia Research
Verified
Journal Article
Closed access
SDStephen I. Deutsch
Stephen I. Deutsch
BSBarbara L. Schwartz
Barbara L. Schwartz
NSNina R. Schooler
Nina R. Schooler
CBClayton H. Brown
Clayton H. Brown
RRRichard B. Rosse
Richard B. Rosse
SRStephanie M. Rosse
Stephanie M. Rosse

1 May 2014 in Clinical Neuropharmacology
Verified
Journal Article
Closed access
MUMaria Urbano
Maria Urbano
LOLeonore Okwara
Leonore Okwara
PMPaul Manser
Paul Manser
KHKathrin Hartmann
Kathrin Hartmann
AHAmy Bs Herndon
Amy Bs Herndon
SDStephen I. Deutsch
Stephen I. Deutsch
Objectives Autism spectrum disorders (ASDs) have core impairments in social communication as well as the presence of repetitive, stereotypic behaviors and restricted interests. Older adolescents and young adults are particularly impacted by these deficits. Preclinical data implicate glutamatergic dysfunction in the pathophysiology of ASDs. D-Cycloserine (DCS), a partial glycineB agonist at the N-methyl-D-aspartic acid receptor site, has been shown to improve sociability in mouse models and a small human study. The sensitivity of the obligatory glycineB co-agonist binding site may change with daily administration of DCS as a result of agonist-induced desensitization. The efficacy of a “pulsed” once-weekly administration versus “daily” administration of DCS was compared. Methods Males and females, ages 14 to 25 years, with a Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition Text Revision diagnosis of an ASD were enrolled in a double-blind, randomized 10-week trial consisting of 8 weeks of active drug with either weekly or daily administration of 50 mg of DCS followed by a 2-week follow-up visit. Results For the purposes of this study, no statistical or clinical differences existed between the 2 dosage groups on the Aberrant Behavior Checklist subscale 3, which measures stereotypies/repetitive movements. When combining groups, a statistically significant decrease of 37% was found from baseline to week 8 when study drug was completed using a linear mixed effects model (P = 0.003). Conclusions D-Cycloserine was shown to be effective in improving stereotypic symptoms in older adolescents and young adults with ASDs measured by the Aberrant Behavior Checklist subscale 3. In addition, DCS was safe and well tolerated.

1 January 2014 in Brain Research Bulletin
Verified
Journal Article
Closed access
JBJessica A. Burket
Jessica A. Burket
ABAndrew D. Benson
Andrew D. Benson
Amy TangAmy Tang
Amy Tang
SDStephen I. Deutsch
Stephen I. Deutsch

1 May 2014 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Closed access
SDStephen I. Deutsch
Stephen I. Deutsch
Amy TangAmy Tang
Amy Tang
JBJessica A. Burket
Jessica A. Burket
ABAndrew D. Benson
Andrew D. Benson

1 July 2015 in Progress in Neuro-Psychopharmacology and Biological Psychiatry
Verified
Journal Article
Closed access
JBJessica A. Burket
Jessica A. Burket
ABAndrew D. Benson
Andrew D. Benson
Amy TangAmy Tang
Amy Tang
SDStephen I. Deutsch
Stephen I. Deutsch